Structure Therapeutics Inc. American Depositary Shares 12th Annual Cantor Fitzgerald Global Healthcare Conference

Thank you, Prakhar, for having us.

Yeah. What we have, we are really laser-focused right now on clinical execution. We have started our Phase III ACCOMPLISH-1 and ACCOMPLISH-2 studies. That is a global study. That is now initiated, and we are focused on recruit to retain, make sure the quality of that Phase III study is as good as possible. Dr. Blai Coll, our Chief Medical Officer, he is leading that. That is our oral GLP-1 small molecule. That is right now looking at potentially best-in-class profile. Quite excited about that. The other program that we have now entered Phase 2a is our amylin. That is ACCG-2671. That has now started a Phase 2a 12-week study and multiple ascending dose. We have that. We have a couple of data readouts coming up. We just had a data readout on Tuesday of this week. That was both on our amylin program and on our aleniglipron GLP-1 program.

We have additional data coming out in Q4. That is our body composition, our type 2 diabetes, and our switch study from injectable. We will also enter the clinic with our second amylin molecule by the end of this year, our combination GLP-1/GIP. Then in the first half of next year, we will read out our 12-week MAD study on our amylin ACCG-2671. So a lot of activity in the next 12 months in addition to the Phase III that will read out at the end of 2028.

Yeah. First of all, what I think is great, I was telling somebody earlier, it was a year ago that we were here at the Cantor conference.

Yeah. I was talking with you, and the debate was, is there really room for an oral GLP-1?

The injectables are just fine, is what many people are saying. Now, first of the year, we had the oral Wegovy launch, and then in April, we had the Foundayo launch. Those two medicines have already taken up 17% of the market. They have already sort of taken in the GLP-1 space. 80% are new entrants, are the naive patients, so they are expanding the market. So what we are seeing is, from the market, there is a huge demand. It is expected oral GLP-1s will take up 50% of the market by 2030. So a lot has changed just in the past year. The oral GLP-1 market has really grown and expanded, and I do not see it slowing down anytime soon.

Yeah. The reason why we started Structure Therapeutics is around accessibility. I am going to look at there is only roughly 10 million people, or 11 million to 13 million, I think is the latest number, of people that are getting access to this class of medicines today. That is a small percentage. Only 1% of the market is currently being penetrated. There is such a demand and there is a lack of access to this class of medicines. Part of this is when I think about accessibility, it is affordability, cost of goods, it is cold chain requirement, the shipping and everything. There is a lot of different features to it. It is oral. Think about global. Not everybody wants a needle. Patients want options. What was fascinating at JP Morgan, one of the things that just resonated with me so much was so many people were telling me, "Oh, my father can finally get on a GLP-1," because he did not want a needle.

He was waiting for the pill. I am seeing somebody nodding their head yes. Exactly the sort of the case. I think that with small molecules, those are all the advantages, cost of goods, manufacturing, scalability, no cold chain requirements. There are so many advantages to small molecules. Small molecules will eventually dominate this space.

I am going to start with our amylin. A lot of excitement around that program. This is the first human clinical data for an oral amylin small molecule. First of all, one of the highlights, 6-day half-life. This gives us opportunity both for daily dosing as well as potential for weekly dosing in a more long-term maintenance study. The safety profile, very clean safety profile. Really pleased with that. Then we had three different levels of target engagement. First, at our 1 and 2 milligram dose, no AEs. Really clean. Is the drug working? At our 5 and 10 milligram dose, we saw a target engagement. The second level was weight loss. Again, this wasn't done as a weight loss study, so this was purely exploratory. When they come back in for final check, we weigh them.